Mast cells, extracellular matrix components, TGFβ isoforms and TGFβ receptor expression in labial salivary glands in systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 59, Issue 3, 2000, Pages 183-189

  Mason, Gillian I ^a   Hamburger, John ^a   Matthews, John B ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ELASTIN; FIBRONECTIN; MATRIX PROTEIN; TENASCIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL POPULATION; COLLAGEN SYNTHESIS; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MAST CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND; SYSTEMIC SCLEROSIS; VASCULAR ENDOTHELIUM; WOUND HEALING;

ADULT; AGED; AGED, 80 AND OVER; DENDRITIC CELLS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MAST CELLS; MIDDLE AGED; PROTEIN ISOFORMS; RAYNAUD DISEASE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SALIVARY GLANDS; SCLERODERMA, SYSTEMIC; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN;

EID: 0034071584     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.59.3.183     Document Type: Article

References (36)

1. 1 Sollberg S, Krieg T. New aspects in scleroderma research. Int Arch Allergy Immunol 1996;111:330-6.
2. 2 Buckingham RB, Prince RK, Rodnam GP. Progressive systemic sclerosis (PSS, Scleroderma) dermal fibroblasts synthesise increased amounts of glycosaminoglycan. J Lab Clin Med 1983;5:659-99.
3. 3 Harrington AB, Dewar HA. A case of Sjogren's disease with scleroderma. BMJ 1951;1:1302.
4. 4 Alarcon-Segovia D, Ibanez G, Hernandex-Ortiz J, Velasquez-Forero F, Gonzalez-Jimenez Y. Sjogren's syndrome in progressive sclerosis (scleroderma). Am J Med 1974;57:78-85.
5. 5 Janin A, Gosselin B, Gosset D, Hatron PY, Sauvezie B. Histological criteria of Sjogren's syndrome in scleroderma. Clin Exp Rheumatol 1989;7:167-9.
6. 6 Hebbar M, Lassalle P, Janin A, Vanhee D, Bisiau S, Hatron PY, Tonnel AB, et al. E-selectin expression in salivary endothelial cells and sera from patients with systemic sclerosis. Role of residual mast cell derived tumor necrosis factor alpha. Arthritis Rheum 1995;38:406-12.
7. 7 Fine A, Goldstream RH. The effect of transforming growth factor beta on cell proliferation and collagen formation. J Biol Chem 1987;262:3897-902.
8. 8 Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J Exp Med 1987; 165:251-62.
9. 9 Wahl SM, Hunt DA, Wakefield LM, McCartneyfrancis N, Wahl LM, Roberts AB, et al. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987;84: 5788-792.
10. 10 Shah M, Foreman DM, Ferguson MWJ. Neutralization of TGF beta 1 and TGF beta 2 on exogenous addition of TGF beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995;108:985-1002.
11. 11 Lawrence DA. Transforming growth factor-beta: a general review. Eur Cytokine Netw 1996;7:363-74.
12. 12 Cotton SA, Herrick AI, Jayson MIV, Freemont AJ. TGF beta - A role in systemic sclerosis? J Pathol 1998;184:4-6.
13. 13 Hebbar M, Gillot J-M, Hachulla E, Lassalle P, Hatron P-Y, Devulder B, et al. Early expression of E-Selectin, tumor necrosis factor alpha and mast cell infiltration in the salivary glands of patients with systemic sclerosis. Arthritis Rheum 1996;39:1161-5.
14. 14 Quaglino D, Bergamini G, Boraldi F, Manzini E, Davidson JM, Ronochetti JR. Connective tissue in skin biopsies from patients suffering systemic sclerosis. J Submicrosc Cytol Pathol 1996;28:287-96.
15. 15 Postlethwaite AE, Keski-Oja J, Balian G, Kang AH. Induction of fibroblast chemotaxis by fibronectin-localization of the chemotactic region to a 140,000 molecular weight non-gelatin binding region. J Exp Med 1981;153:494-9.
16. 16 Tsukamoto Y, Helsel WE, Wahl SM. Macrophage production of fibronectin: a chemoattractant for fibroblasts. J Immunol 1981;127:673-8.
17. 17 Chiquet-Ehrismann R, Kalla P, Pearson CA, Beck K, Chiquet M. Tenascin interferes with fibronectin action. Cell 1988;53:383-90.
18. 18 Hawkins RA, Claman HN, Clark RAF, Steigerwald JC. Increased dermal mast cell populations in progressive systemic sclerosis: A link in chronic fibrosis? Ann Int Med 1985;102:182-6.
19. 19 Vitali C, Bombardieri S, Moutsopoulo HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjogren's syndrome. Arthritis Rheum 1993;36:340-7.
20. 20 Koski H, Konttinen YT, Gu X-H, Hietanen J, Malmstrom M. Transforming growth factor beta 2 in labial salivary glands in Sjogren's syndrome. Ann Rheum Dis 1995;54: 744-7.
21. 21 Cauli A, Yanni G, Pitzalis C, Challacombe S, Panayi GS. Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjogren's syndrome and chronic sialadenitis. Ann Rheum Dis 1995;54:209-15.
22. 22 Kizu Y, Sakurai H, Katagiri S, Shinozaki N, Ono M, Tsubota K, et al. Immunohistological analysis of transforming growth factor beta-1 expression in normal and inflamed salivary glands. J Clin Pathol 1996;49:728-32.
23. 23 Laitinen A, Altraja A, Kampe M, Linden M, Virtanen I, Laitinen LA. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am J Respir Crit Care Med 1997;156:951-8.
24. 24 Riedl S, Kadmon M, Tandara A, Hinz U, Moller P, Herfarth C, et al. Mucosal tenascin C content in inflammatory and neoplastic diseases of the large bowel. Dis Colon Rectum 1998;41:86-92.
25. 25 Smith AJ, Hall RC, Matthews JB. Regulatory factors for transforming growth factor-β1 (TGFβ1) in dentine matrix. Eur J Oral Sci 1998;14:179-84.
26. 26 Sloan AJ, Matthews JB, Smith AJ. TGFβ receptor expression in human odontoblasts and pulpal cells. Histochem J 1999; 31:565-9.
27. 27 Wright HJ, Chapple ILC, Matthews JB. Expression of TGFβ isoforms and receptors in drug-induced gingival overgrowth. J Dent Res 1999;78:1065.
28. 28 Sfikakis PP, McCune BK, Tsokos M, Aroni K, Vayiopoulous G, Tsokos GC. Immunohistological demonstration of transforming growth factor beta isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol 1993;69:199-204.
29. 29 Feghali CA, Wright TM. Identification of multiple, differentially expressed mRNAs in dermal fibroblasts from patients with systemic sclerosis. Arthritis Rheum 1999;42: 1451-7.
30. 30 Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGFβ receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGFβ signalling to scleroderma phenotype. J Invest Dermatol 1998;110:47-51.
31. 31 Gruschwitz M, Muller PV, Sepp N, Hofer E, Fontana A, Wick G. Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis. A mediator of fibrosis. J Invest Dermatol 1990;94:197-203.
32. 32 Russel JD, Russel SB, Trupin KM. The effects of histamine on the growth of cultured fibroblasts isolated from normal and keloid tissue. J Cell Physiol 1977;93:389-94.
33. 33 Claman HN. Mast cells, T cells and abnormal fibrosis. Immunol Today 1985;6:192-5.
34. 34 Claman HN. On scleroderma-mast cells, endothelial cells, and fibroblasts. JAMA 1989;262:1206-9.
35. 35 Cohen T, Trigg P, Eady RAJ. Distribution of mast cells in human dermis: development of a mapping technique. Br J Dermatol 1979;100:635-40.
36. 36 Matthews JB, Potts AJC, Hamburger J, Scott DGI. T6 antigen-positive cells in human labial salivary glands. Arch Oral Biol 1985;30:325-9.